Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

Phase 2

Completed

Conditions: Infection Viral
Thromboses, Venous
COVID-19

Interventions: Drug: Enoxaparin Prefilled Syringe [Lovenox]

First Posted Date: 2020-04-21

Last Posted Date: 2022-10-12

Lead Sponsor: Johns Hopkins All Children's Hospital

Target Recruit Count: 40

Registration Number: NCT04354155

Locations: 🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Hospital and Children's Center, Baltimore, Maryland, United States
🇺🇸
Rady Children's Hospital, San Diego, California, United States

and more 13 locations

Preventing COVID-19 Complications With Low- and High-dose Anticoagulation

Phase 3

Terminated

Conditions: Sars-CoV2
COVID

Interventions: Drug: Enoxaparin

First Posted Date: 2020-04-15

Last Posted Date: 2021-09-14

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 160

Registration Number: NCT04345848

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
🇨🇭
Ospedale Regionale di Locarno, Locarno, Switzerland
🇨🇭
Hôpital du Valais, Sion, Switzerland

and more 1 locations

Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

Not Applicable

Completed

Conditions: Postpartum DVT
Thromboembolism
Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2020-03-12

Last Posted Date: 2022-01-28

Lead Sponsor: University of Utah

Target Recruit Count: 146

Registration Number: NCT04305756

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Warfarin Initiation in Mechanical Mitral Valve Replacement Patients

Phase 4

Completed

Conditions: Mitral Valve Disease

Interventions: Drug: Warfarin Sodium 3 MG
Drug: Warfarin Sodium 5 MG
Drug: Enoxaparin Sodium 100 MG/ML Prefilled Syringe

First Posted Date: 2020-01-22

Last Posted Date: 2020-01-27

Lead Sponsor: Sarah Sabry Hashem

Target Recruit Count: 50

Registration Number: NCT04235569

Locations: 🇪🇬
The Cardiovascular Hospital, Heliopolis, Cairo, Egypt

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Phase 4

Conditions: Deep Vein Thrombosis
Venous Thromboembolism

Interventions: Drug: Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
Drug: Rivaroxaban 10 milligram Oral Tablet

First Posted Date: 2019-11-19

Last Posted Date: 2020-01-18

Lead Sponsor: Florida Orthopaedic Institute

Target Recruit Count: 128

Registration Number: NCT04169269

Locations: 🇺🇸
Florida Orthopaedic Institute, Tampa, Florida, United States

Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study

Phase 4

Withdrawn

Conditions: Pulmonary Embolism
Deep Venous Thrombosis
Venous Thromboembolism
Bleeding as Surgical Complication (Treatment)

Interventions: Drug: Receipt of enoxaparin
Drug: Placebo

First Posted Date: 2019-06-17

Last Posted Date: 2021-10-08

Lead Sponsor: University of Utah

Registration Number: NCT03988231

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Phase 2

Completed

Conditions: Arthroplasty, Replacement, Knee

Interventions: Drug: JNJ-70033093 200 mg
Drug: JNJ-70033093 50 mg
Drug: JNJ-70033093 25 mg
Drug: JNJ-70033093 100 mg
Drug: Enoxaparin 40 mg
Drug: Placebo

First Posted Date: 2019-03-27

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1242

Registration Number: NCT03891524

Locations: 🇦🇷
Clinica Adventista Belgrano, Caba, Argentina
🇧🇷
Hospital e Maternidade Dr Christovao da Gama S.A, Santo Andre, Brazil
🇭🇺
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz, Szekesfehervar, Hungary

and more 114 locations